Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06538389CT.gov High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ductal Breast Carcinoma In Situ
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brc-001 (this asset) | City of Hope Medical Center | P2 | CCC · 53 |
| Ropivacaine | Zealand University Hospital | P4 | BB |
| Sufentanyl | Zealand University Hospital | P4 | BB |
| Anastrozole | Alliance for Clinical Trials in Oncology | P3 | BB |
| (Z)-Endoxifen | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) | P2 | BB |
| Oxybutynin | Academic and Community Cancer Research United | P3 | BB |
| Letrozole | Alliance for Clinical Trials in Oncology | P3 | BB |
| Metformin | M.D. Anderson Cancer Center | P3 | BB |
| Tamoxifen | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Ductal Breast Carcinoma In Situ cohort
Other indications for Brc-001
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma In Situ | — | P2 | CCC · 53 |
| Breast Cancer | — | P2 | CCC · 53 |
| Breast Adenocarcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brc-001 in Ductal Breast Carcinoma In Situ. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brc-001-ductal-breast-carcinoma-in-situ
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →